患有心血管疾病的老年人中的SGLT2抑制剂:系统性审查和元分析
Kota Minami1, Rika Terashima2,3, Lina Freeman4
1Medical Training Center, Saga University Hospital, Saga, Japan.
Journal of the American Geriatrics Society
|October 7, 2025
概括
-葡萄糖共运输体-2 (SGLT2) 抑制剂显著降低心血管疾病的老年人心血管风险. 这些发现支持它们的使用,强调仔细监测潜在的与年龄有关的风险.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 老年病的医生 老年病的医生
背景情况:
- -葡萄糖共运输体-2 (SGLT2) 抑制剂是已确立的2型糖尿病 (T2DM) 的治疗方法.
- 这些药物已经证明了超出血糖控制的显著心脏和脏效益.
- 对患有心血管疾病 (CVD) 的老年人进行证据综合是有限的.
研究的目的:
- 系统地审查和分析SGLT2抑制剂在患有心血管疾病的老年人 (≥65岁) 的疗效.
- 评估对复合心血管结果,全因死亡率,心血管死亡和心力衰竭住院治疗的影响.
- 评估各种子组的安全性和有效性.
主要方法:
- 从2015年1月到2025年1月的随机对照试验 (RCT) 的系统审查和元分析.
- 包括专注于先前患有心血管疾病的老年人 (≥65岁) 的研究.
- 主要结局:由于心力衰竭 (HHF) 入院,紧急心力衰竭 (HF) 访问和心血管死亡 (CVD) 的综合结合.
主要成果:
- SGLT2 抑制剂显著降低了复合结果 (HR:0.75),所有原因死亡率 (HR:0.80),心血管疾病 (HR:0.78) 和高血压 (HR:0.73).
- 在包括心力衰竭,T2DM和老年阶层 (≥75岁) 在内的各个子组中,益处是一致的.
- 人们注意到生殖器感染的风险增加,但其他严重不良事件减少了.
结论:
- SGLT2 抑制剂在降低患有心血管疾病的老年人主要心血管不良事件方面表现出显著的有效性.
- 研究结果支持在这个人群中使用SGLT2抑制剂,特别是对于那些患有HF或T2DM的人.
- 建议仔细监测不良事件,如生殖器感染.
相关概念视频
Drug Dosing: Geriatric Patients
225
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
225
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
227
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
227
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution
232
Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...
232
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
196
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
196
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
234
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
234
Pharmacodynamics in Geriatric Patients: Effects of Age
187
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
187

